← Markets

Atai Beckley Inc.

ATAI · NASDAQ

Market closed$7.22$0.070000 (+0.98%)After hours $7.14 · -1.10%

Key statistics

Previous close$7.15
Open$7.12
Day high$7.22
Day low$7.08
52-week high$7.22
52-week low$3.06
Market cap2.66B
Volume41.55M
Average volume10.95M
P/E ratio-13.13
Forward P/E—
EPS-0.55
Dividend yield0.00%

Market context

Why it moved

ATAI shares edged higher as investor optimism around the contingent value rights continued to support the stock above Eli Lilly's acquisition price of $6.75 per share, following the landmark $2.8 billion buyout announcement that sent the stock surging over 33% the prior session.

Investing.comInvesting.comInvesting.comInvesting.comTimothysykes

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026AtaiBeckley closed modestly higher, edging up near its 52-week high as merger arbitrage dynamics continued to play out following Eli Lilly's definitive agreement to acquire the company for $6.75 per share in cash ($2.8B upfront, up to $3.8B including milestone CVRs). The ~$0.47 spread between the current price and the cash offer reflects the market pricing of one CVR worth up to $2.50 tied to BPL-003 and VLS-01 milestones, alongside closing and timing risk. Volume surged to over 4x the average, with analysts broadly downgrading to Hold post-announcement while Canaccord and Oppenheimer maintained bullish targets citing pipeline upside.

0.979

July 17, 2026AtaiBeckley surged 33% after Eli Lilly announced a definitive agreement to acquire the psychedelic drug developer for $2.8 billion upfront ($6.75/share in cash), plus up to $1 billion in contingent value rights tied to development and regulatory milestones for BPL-003 and VLS-01 — valuing the deal at up to $3.8 billion. The acquisition centers on BPL-003, an intranasal DMT-based therapy in Phase 3 trials for treatment-resistant depression that has shown rapid and durable antidepressant effects. Shares closed near their 52-week high on volume over 20x the daily average, though in after-hours trading they slipped modestly below the $6.75 deal price, reflecting a slight discount to the upfront consideration as investors weigh deal-close risk.

33.3955

July 16, 2026AtaiBeckley shares closed down nearly 5.5% during the regular session but are surging over 64% in after-hours trading after Bloomberg and Reuters reported that Eli Lilly is nearing a deal to acquire the psychedelic drugmaker. The potential acquisition caps a period of strong momentum for AtaiBeckley, which had already rallied on favorable FDA guidance for psychedelic drug trials, a Canaccord price target raise to $17 with a Buy rating, and completion of dosing in its Phase 2b Elumina trial of VLS-01 for treatment-resistant depression — with topline results expected in Q4 2026.

-5.4674

July 15, 2026AtaiBeckley surged after final FDA guidance for psychedelic-drug trials highlighted the cost advantages of BPL-003's shorter two-hour clinic model, as the agency outlined requirements for two monitors per session — making session duration a meaningful operating cost variable. The move was further supported by a recent HHS-VA memorandum of understanding expected to boost psychedelic drug developers, and a Q4 2026 topline readout catalyst for VLS-01 following full enrollment of the Elumina Phase 2b depression trial. Volume ran roughly 54% above the 65-day average, reflecting broad investor participation in the psychedelic biotech space.

14.0845

July 14, 2026AtaiBeckley declined nearly 4% as broader market weakness — driven by renewed U.S.-Iran military tensions and surging oil prices — weighed on risk assets, overshadowing a pair of company-specific catalysts. The FDA finalized guidance on psychedelic drug development, which Jefferies flagged as a positive for developers including AtaiBeckley, and the company separately announced it had dosed the final patient in its 156-patient Phase 2b Elumina trial of VLS-01 for depression. Despite a broadly bullish backdrop for biotech M&A and the psychedelic medicine theme, ATAI continues to trade far below its analyst consensus target of $15.50, reflecting ongoing investor caution around its pre-revenue stage, widening losses, and dilution risk.

-3.8685

July 11, 2026AtaiBeckley declined 3% amid emerging valuation concerns and insider selling activity, even as its clinical pipeline continues to advance. Director Robert Hershberg sold 100,000 shares at ~$4.96 under a 10b5-1 plan on July 7, adding to investor caution. Analysts at Canaccord, Guggenheim, and H.C. Wainwright hold bullish price targets ($15–$25), citing Q4 2026 topline data from the Phase 2b VLS-01 depression trial and a cash runway into 2029, but valuation screens—including a P/B of 9.6x vs. a sector average of ~2.4x—have prompted concerns that optimism may already be priced in.

-3.0019

July 10, 2026AtaiBeckley shares rose amid a favorable biotech backdrop, recovering from last week's initial sell-off following completion of VLS-01 Phase 2b Elumina dosing. Canaccord Genuity raised its price target to $17 (from $15) while reiterating a Buy rating, citing plans to advance VLS-01 into Phase 3 for major depressive disorder pending Q4 2026 topline data—while BPL-003, holding Breakthrough Therapy Designation, advances through Phase 3 for treatment-resistant depression. Broader sector tailwinds also supported the move, with Jim Cramer calling biotech "the hottest group in the market" and predicting an M&A wave under more favorable FDA leadership.

3.0948

July 9, 2026AtaiBeckley closed essentially flat, edging down modestly amid a broad market risk-off session driven by President Trump declaring the U.S.-Iran ceasefire 'over,' sending oil surging and equities lower. Investor attention remains squarely on the company's pipeline after it announced on July 6 that the last patient was dosed in its Phase 2b Elumina trial of VLS-01 for treatment-resistant depression, with topline data due Q4 2026. Sentiment is further supported by Jim Cramer calling biotech 'the hottest group in the market' and predicting a wave of M&A, while multiple institutional investors—including UBS, Millennium Management, and BlackRock—meaningfully added to ATAI positions in Q1 2026, and analysts maintain Buy ratings with a median price target of $15.

-0.3854

Seeking Alpha · July 16, 2026AtaiBeckley jumps 30% as Eli Lilly agrees to buy psychedelic firm for up to $3.8B (LLY:NYSE)Reuters · July 16, 2026Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley dealPR Newswire · July 16, 2026Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsBioPharma Dive · July 16, 2026Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
Benzinga · July 17, 2026Guggenheim Downgrades AtaiBeckley to Neutral
Benzinga · July 16, 2026Canaccord Genuity Downgrades AtaiBeckley to Hold, Announces $8 Price Target
Benzinga · July 16, 2026Why Is GH Research Stock Trading Higher on Thursday?
Benzinga · July 16, 2026AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal
Mt Newswire · July 16, 2026Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion to Expand Neuroscience Pipeline
Mt Newswire · July 16, 2026Sector Update: Healthcare Stocks Rise Pre-Bell Thursday
Mt Newswire · July 16, 2026Eli Lilly to Acquire AtaiBeckley for $2.8 Billion in Cash, Up to $1 Billion in Milestone Payments
Mt Newswire · July 16, 2026Market Chatter: Eli Lilly in Talks to Acquire AtaiBeckley

Peers

S&P 500SPX · $7,457.69-1.01%COMPASS Pathways plcCMPS · $12.35-0.64%MiniMed Group, Inc. Common StockMMED · $16.93+6.61%Bright Minds Biosciences Inc.DRUG · $76.12+2.55%Numinus Wellness Inc.NUMIF · $0.039000-2.50%Mirum Pharmaceuticals, Inc.MIRM · $118.86+1.28%Rhythm Pharmaceuticals, Inc.RYTM · $106.60+0.48%PTC Therapeutics, Inc.PTCT · $78.59+0.09%Cronos Group Inc.CRON · $2.79+1.45%Xeris Biopharma Holdings, Inc.XERS · $8.80+1.27%Amylyx Pharmaceuticals, Inc.AMLX · $17.75+4.29%Nuvation Bio Inc.NUVB · $5.80+2.84%